Clinical Trial 5484

Indianapolis, IN 46260


Study Summary:

We are currently conducting a study to demonstrate that subjects who receive an 8-day series of otelixizumab infusions have greater improvement than subjects who receive placebo in endogenous insulin secretion, as assessed by area under the concentration-time curve for mixed meal-stimulated C-peptide, at 12 months after study drug administration.


Qualified Participants Must:

• Be 18-35 years of age
• Have a diagnosis of diabetes Type 1 with an interval of less than or equal to 90 days between the initial diagnosis and the first dose of study drug
• Currently be receiving insulin treatment for T1DM


Qualified Participants May Receive:

Up to $1,300 monetary compensation.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.